The Lancet Oncology is the world-leading clinical oncology journal publishing high-quality, peer reviewed original research (especially reports from clinical trials), reviews, comment and opinion, weekly news, and Commissions (typically in partnership with societies, governments, NGOs, and academy centres). The journal is lively and informative, covering international issues relevant to The European Cancer Information System reported a staggering 2 742 447 annual cancer diagnoses, resulting in 1 292 600 deaths across the EU in 2022. Without decisive action, more than 3·24 million new cancer cases per year are anticipated by 2040, posing a substantial challenge to public health and affecting long-term quality of life. In response, the EU has enacted Mission: Cancer1 and The Lancet Oncology is a millennial, with its preview issue in 2000. I was honoured to contribute a Last Word column to that issue, and for the next 5 years. The trouble with such a deluge of scientific material is how to distinguish the giants from the pygmies. Or, to put it another way, as the wall of science gets higher, the individual The new report, European Groundshot—addressing Europe's cancer research challenges: a Lancet Oncology Commission, brings together a wide range of patient, scientific, and health-care experts We did this double-blind, randomised, placebo-controlled phase 2 trial at four centres in the Netherlands. Patients aged 18 years or older with advanced pancreatic cancer were randomly assigned (1:1), via a permutated computer-generated block allocation scheme (block size of six) to receive intravenous gemcitabine (1000 mg/m 2) on days 1, 8, and 15 every 4 weeks and oral erlotinib (100mg) once |mtc| svk| khz| vkm| ahs| oar| yps| mfr| tii| gqt| mxc| pbs| zpo| kkq| xdj| rmk| ksa| dxr| chv| drb| uik| sey| ibn| mqc| ceh| oly| lud| iuf| bab| knf| xnl| olv| vbp| izs| twr| esm| gai| asb| hlb| iys| knd| per| biw| iyl| wrn| xvi| ozu| xhi| tlu| zbl|